Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 6/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562856 | 1.00 | SNCA (0.52) | SNCAL3MBTL1NFE2L2DHODHNQO2 | |
| SCHEMBL4012937 | 0.81 | HTR2A (0.52) | L3MBTL1DHODH | |
| SCHEMBL4012940 | 0.81 | HTR2A (0.52) | L3MBTL1DHODH | |
| SCHEMBL9000394 | 0.80 | L3MBTL1 (0.51) | SNCAL3MBTL1NFE2L2NPC1ALOX15 | |
| SCHEMBL27831701 | 0.77 | BACE1 (0.59) | SNCANFE2L2LMNA | |
| SCHEMBL2561503 | 0.76 | L3MBTL1 (0.57) | L3MBTL1NFE2L2NPC1RAB9AALOX15 | |
| SCHEMBL30852225 | 0.76 | L3MBTL1 (0.53) | L3MBTL1NFE2L2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4014140 | 0.75 | HTR2A (0.45) | SNCADHODH | |
| SCHEMBL4014145 | 0.75 | HTR2A (0.45) | SNCADHODH | |
| SCHEMBL535731 | 0.75 | L3MBTL1 (0.55) | L3MBTL1NFE2L2ALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | SNCA 4506/4885L3MBTL1 1562/4885NFE2L2 2688/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | SNCA 4573/4885L3MBTL1 1573/4885NFE2L2 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.